Your browser doesn't support javascript.
loading
Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis.
Broséus, Julien; Hergalant, Sébastien; Vogt, Julia; Tausch, Eugen; Kreuz, Markus; Mottok, Anja; Schneider, Christof; Dartigeas, Caroline; Roos-Weil, Damien; Quinquenel, Anne; Moulin, Charline; Ott, German; Blanchet, Odile; Tomowiak, Cécile; Lazarian, Grégory; Rouyer, Pierre; Chteinberg, Emil; Bernhart, Stephan H; Tournilhac, Olivier; Gauchotte, Guillaume; Lomazzi, Sandra; Chapiro, Elise; Nguyen-Khac, Florence; Chery, Céline; Davi, Frédéric; Hunault, Mathilde; Houlgatte, Rémi; Rosenwald, Andreas; Delmer, Alain; Meyre, David; Béné, Marie-Christine; Thieblemont, Catherine; Lichter, Peter; Ammerpohl, Ole; Guéant, Jean-Louis; Guièze, Romain; Martin-Subero, José Ignacio; Cymbalista, Florence; Feugier, Pierre; Siebert, Reiner; Stilgenbauer, Stephan.
Afiliação
  • Broséus J; Division of CLL. Department of Internal Medicine III, Ulm University, Ulm, Germany. julien.broseus@univ-lorraine.fr.
  • Hergalant S; Inserm UMRS1256 Nutrition-Génétique et Exposition aux Risques Environnementaux (N-GERE), Université de Lorraine, Nancy, France. julien.broseus@univ-lorraine.fr.
  • Vogt J; Université de Lorraine, CHRU-Nancy, Service d'Hématologie Biologique, Pôle Laboratoires, F54000, Nancy, France. julien.broseus@univ-lorraine.fr.
  • Tausch E; Inserm UMRS1256 Nutrition-Génétique et Exposition aux Risques Environnementaux (N-GERE), Université de Lorraine, Nancy, France.
  • Kreuz M; Institute of Human Genetics, Ulm University & Ulm University Medical Center, Ulm, Germany.
  • Mottok A; Division of CLL. Department of Internal Medicine III, Ulm University, Ulm, Germany.
  • Schneider C; Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany.
  • Dartigeas C; Institute of Human Genetics, Ulm University & Ulm University Medical Center, Ulm, Germany.
  • Roos-Weil D; Division of CLL. Department of Internal Medicine III, Ulm University, Ulm, Germany.
  • Quinquenel A; Department of Haematology, University Hospital of Tours, Tours, France.
  • Moulin C; Department of Hematology, Hôpital de la Pitié-Salpêtrière, AP-HP, Paris, France.
  • Ott G; Université de Reims Champagne-Ardenne, IRMAIC, Centre Hospitalier Universitaire de Reims, Hématologie Clinique, Reims, France.
  • Blanchet O; Department of Hematology, University Hospital of Nancy, Vandoeuvre-lès-Nancy, France.
  • Tomowiak C; Inserm, CHRU, University of Lorraine, CIC Clinical Epidemiology, Nancy, France.
  • Lazarian G; Department of Clinical Pathology, Robert-Bosch-Krankenhaus, and Dr. Margarete Fischer-Bosch Institute for Clinical Pharmacology, Stuttgart, Germany.
  • Rouyer P; CHU Angers, Biological Resource Center of Angers (CRB-CHU Angers), BB-0033-00038, Laboratoire d'Hématologie, Angers, France.
  • Chteinberg E; Department of Hematology, CHU Poitiers, Poitiers, France.
  • Bernhart SH; CIC1402 Inserm Poitiers, Poitiers, France.
  • Tournilhac O; Hematology Laboratory, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
  • Gauchotte G; Inserm UMRS1256 Nutrition-Génétique et Exposition aux Risques Environnementaux (N-GERE), Université de Lorraine, Nancy, France.
  • Lomazzi S; Institute of Human Genetics, Ulm University & Ulm University Medical Center, Ulm, Germany.
  • Chapiro E; Bioinformatics Group, Department of Computer Science and Interdisciplinary Center for Bioinformatics, Leipzig University, Leipzig, Germany.
  • Nguyen-Khac F; Hematology department, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.
  • Chery C; Inserm UMRS1256 Nutrition-Génétique et Exposition aux Risques Environnementaux (N-GERE), Université de Lorraine, Nancy, France.
  • Davi F; Department of Biopathology CHRU-ICL, BBB, CHRU Nancy, Vandoeuvre-lès-Nancy, France.
  • Hunault M; Biological Resource Center of Nancy, BB-0033-00035, CHRU de Nancy, Nancy, France.
  • Houlgatte R; Sorbonne Université, Cytogénétique Hématologique, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France.
  • Rosenwald A; Centre de Recherche des Cordeliers, INSERM, Université Sorbonne Paris Cite, Université Paris Descartes, Université Paris Diderot, F-75006, Paris, France.
  • Delmer A; Sorbonne Université, Cytogénétique Hématologique, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France.
  • Meyre D; Centre de Recherche des Cordeliers, INSERM, Université Sorbonne Paris Cite, Université Paris Descartes, Université Paris Diderot, F-75006, Paris, France.
  • Béné MC; Inserm UMRS1256 Nutrition-Génétique et Exposition aux Risques Environnementaux (N-GERE), Université de Lorraine, Nancy, France.
  • Thieblemont C; CHRU of Nancy, Service de Biochimie-Biologie Moléculaire-Nutrition, Pôle Laboratoires, F54000, Nancy, France.
  • Lichter P; Centre de Recherche des Cordeliers, INSERM, Université Sorbonne Paris Cite, Université Paris Descartes, Université Paris Diderot, F-75006, Paris, France.
  • Ammerpohl O; Hematology Department, Hôpital Pitié-Salpêtrière, AP-HP, Sorbonne University, Paris, France.
  • Guéant JL; Department of Hematology, University Hospital of Angers, Angers, France.
  • Guièze R; Institute of Pathology, University Hospital of Würzburg, Bavaria, Germany.
  • Martin-Subero JI; Université de Reims Champagne-Ardenne, IRMAIC, Centre Hospitalier Universitaire de Reims, Hématologie Clinique, Reims, France.
  • Cymbalista F; Inserm UMRS1256 Nutrition-Génétique et Exposition aux Risques Environnementaux (N-GERE), Université de Lorraine, Nancy, France.
  • Feugier P; Hematology Biology, University Hospital of Nantes, Hôtel-Dieu, France.
  • Siebert R; Inserm 1232 Centre de Recherche en Cancérologie et Immunologie Nantes Angers (CRCINA), Nantes, France.
  • Stilgenbauer S; Department of Hematology, Hôpital Saint-Louis, Paris, France.
Nat Commun ; 14(1): 309, 2023 01 19.
Article em En | MEDLINE | ID: mdl-36658118
ABSTRACT
Richter syndrome (RS) is the transformation of chronic lymphocytic leukemia (CLL) into aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL). We characterize 58 primary human RS samples by genome-wide DNA methylation and whole-transcriptome profiling. Our comprehensive approach determines RS DNA methylation profile and unravels a CLL epigenetic imprint, allowing CLL-RS clonal relationship assessment without the need of the initial CLL tumor DNA. DNA methylation- and transcriptomic-based classifiers were developed, and testing on landmark DLBCL datasets identifies a poor-prognosis, activated B-cell-like DLBCL subset in 111/1772 samples. The classification robustly identifies phenotypes very similar to RS with a specific genomic profile, accounting for 4.3-8.3% of de novo DLBCLs. In this work, RS multi-omics characterization determines oncogenic mechanisms, establishes a surrogate marker for CLL-RS clonal relationship, and provides a clinically relevant classifier for a subset of primary "RS-type DLBCL" with unfavorable prognosis.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B / Linfoma Difuso de Grandes Células B Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B / Linfoma Difuso de Grandes Células B Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha